The effect of early measles vaccination at 4.5 months of age on growth at 9 and 24 months of age in a randomized trial in Guinea-Bissau

BMC Pediatrics

Research Article

A. Rodrigues¹  C. L. Martins¹  P. Aaby²  S. Biering-Sørensen²  S. M. Rasmussen²  A. Andersen²  M. Bjerregaard-Andersen³  S. Byberg⁴  C. S. Benn⁴ 

[1] Bandim Health Project, Indepth Network, Apartado 861, 1004, Bissau Codex, Guinea-Bissau;Bandim Health Project, Indepth Network, Apartado 861, 1004, Bissau Codex, Guinea-Bissau;Bandim Health Project, Research Center for Vitamins and Vaccines (CVIVA), Statens Serum Institut, Artillerivej 5, 2300, Copenhagen S, Denmark;Bandim Health Project, Indepth Network, Apartado 861, 1004, Bissau Codex, Guinea-Bissau;Bandim Health Project, Research Center for Vitamins and Vaccines (CVIVA), Statens Serum Institut, Artillerivej 5, 2300, Copenhagen S, Denmark;Department of Endocrinology, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark;Bandim Health Project, Indepth Network, Apartado 861, 1004, Bissau Codex, Guinea-Bissau;Bandim Health Project, Research Center for Vitamins and Vaccines (CVIVA), Statens Serum Institut, Artillerivej 5, 2300, Copenhagen S, Denmark;OPEN, Odense Patient data Explorative Network, Odense University Hospital/Institute of Clinical Research, University of Southern Denmark, Odense, Denmark;

关键词: Early measles vaccination;    Growth;    Non-specific effects;    Sex-differential effects;    Neonatal vitamin A supplementation;    Season;   

DOI  :  10.1186/s12887-016-0738-z

 received in 2016-07-26, accepted in 2016-11-26,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundProviding an early, additional measles vaccine (MV) at 4.5 months of age has been shown to reduce child mortality in low-income countries. We studied the effects on growth at 9 and 24 months of age.MethodsA randomized controlled trial was conducted in Guinea-Bissau from 2003–2007 including 6,648 children. Children were randomized 1:1:1 to receive Edmonston-Zagreb measles vaccine at 4.5 and 9 months of age (group A), no vaccine at 4.5 months and Edmonston-Zagreb measles vaccine at 9 months (group B), or no vaccine at 4.5 months and Schwarz measles vaccine at 9 months (group C) Data on anthropometrics were obtained at enrolment at 4.5 months of age and again at 9 and 24 months of age. Analyses were stratified by sex, season of enrolment, and neonatal vitamin A supplementation (NVAS) status, as all these factors have been shown to modify the effect of early MV on mortality.ResultsOverall there was no effect of early MV on anthropometry at 9 months. At 24 months children who had received early MV had a significantly larger mid-upper-arm-circumference (MUAC/in cm) (Difference = 0.08; 95% CI (0.02;0.14)) compared with children in the control group; this effect was most pronounced among girls (0.12 (0.03;0.20)). The effect of early MV on MUAC remained significant in the dry season and in girls who received placebo rather than NVAS.ConclusionEarly MV was associated with a larger MUAC particularly in girls. These results indicate that a two-dose measles vaccination schedule might not only reduce child mortality but also improve growth.Trial registrationClinicalTrials.gov NCT00168558. Registered September 9, 2005, retrospectively registered

【 授权许可】

CC BY   
© The Author(s). 2016